U.S. regulators have warned Johnson & Johnson unit Janssen Pharmaceutica that a letter sent to doctors about its Risperdal drug to treat schizophrenia and bipolar mania is misleading. In a warning disclosed on Tuesday, the Food and Drug Administration told Janssen that its November letter failed to disclose information added to Risperdal’s labeling about excess blood sugar and diabetes and minimized the risk of serious events including coma and even death. The FDA also said the letter fails to recommend regular testing for diabetes and “misleadingly claims that Risperdal is safer than other atypical antipsychotics.”
(1 votes, average: 5 out of 5)
Loading ...You can skip to the end and leave a response. Pinging is currently not allowed.
2 Comments to
“J&J Warned on Claims About Antipsychotic Drug”
I finally got a chance to check out your web page, and I must say that I’m impressed. Hope everything is going well. Take care!
I have tried practically every drug on the market including Risperdal. It’s funny how you are not told about side effects and when you are down, you can’t look it up because you just don’t care. I think psychiatrists in general need to be more forthcoming about side effects of meds. I gained a lot of weight on this drug.
Join the Conversation! Post a Comment:
Last reviewed: By John M. Grohol, Psy.D. on 27 Apr 2004
